Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in lupin

Lupin Launches Generic Antifungal Product In US Market

Tavaborole Topical Solution is generic equivalent of Anacor Pharmaceuticals' Kerydin Topical Solution and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Read More

Lupin Arm Gets Supplemental New Drug Application Approval From USFDA For Solosec

Shares of Lupin Ltd closed at Rs 1,146.25 per scrip on BSE, down 0.26 per cent from its previous close.

Read More

Lupin Gets USFDA Nod To Market Sevelamer Hydrochloride Tablets

Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Read More

Lupin Gets UK Marketing Authorisation For Generic Pressurised Metered Dose Inhaler

Shares of Lupin Ltd were trading at Rs 1,195.20 per scrip on BSE, down 2.85 per cent from its previous close.

Read More

Lupin Gets Warning Letter From USFDA For Somerset Facility

Lupin is committed to addressing the concerns raised by the USFDA and will work with the FDA and the New Jersey district to resolve these issues at the earliest

Read More

Lupin Launches Digital Asthma Educator Platform

The new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailments.

Read More

Lupin Launches Generic Inhalation Product In US Market

Shares of Lupin were trading 0.39 per cent up at Rs 1,237.20 apiece on the BSE.

Read More

Lupin To Enter Digital Healthcare Space In India

Shares of Lupin Ltd were trading 0.29 per cent lower at Rs 1,243.30 apiece on BSE.

Read More

Lupin Reports 18 % Increase In Q4 Net Profit At Rs 460 Cr; FY21 Profit At Rs 1,216 Cr

The drug firm noted that its capital expenditure for the fourth quarter stood at Rs 140 crore and for the full year (FY21) at Rs 628 crore.

Read More

Lupin, Sun Pharma, Jubilant Cadista Recall Drugs In US Market

The affected lot has been produced by Jubilant Generics at its Roorkee based plant in Uttarakhand and marketed in the US by Salisbury-based Jubilant Cadista Pharmaceuticals, Inc.

Read More

Lupin Launches Generic Diarrhea Drug In US Market

Nitazoxanide tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.

Read More

Lupin Gets USFDA Nod For Generic Diabetes Drug

As per IQVIA MAT November 2020 data, Empagliflozin and Metformin Hydrochloride ER Tablets had estimated annual sales of USD 357 million in the US.

Read More

Lupin, Concord Biotech Get USFDA Nod For Generic Immunosuppressant Capsules

The product is a generic version of Astellas Pharma US, Inc's Prograf capsules in the same strengths

Read More

Lupin Q2 Net Profit At Rs 211 Cr

Consolidated total revenue from operations of the company stood at Rs 3,835 crore for the quarter under consideration. It was Rs 3,822.21 crore for the same period a year ago

Read More

Contract Advertising creates a series of 10-second films for Lupin’s Lupisafe Wipes

Lupin has launched Lupisafe Wipes – a wipe with 70% alcohol that kills 99.9% germs. Infused with the goodness of aloe vera, Lupin’s wipes are safe to use on hands, apart from surfaces and gadgets.

Read More